Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DORIC trial of cediranib plus gefitinib versus cediranib plus placebo in recurrent or progressive glioblastoma
2010-021531-13Phase 2Completed
- Sponsor
- UCLH
- Start
- Jan 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in glioblastoma (GBM) comparing Cediranib + Iressa with Cediranib + placebo (2 arms). Primary endpoint: Progression-free survival. Started Jan 2011; status: completed.
02
Drugs
cediranibgefitinib
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on 2010-021531-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-021531-13.